دورية أكاديمية
أعرض في EDS

Effectiveness and safety of rituximab in special types of rheumatoid arthritis.

التفاصيل البيبلوغرافية
العنوان: Effectiveness and safety of rituximab in special types of rheumatoid arthritis.
المؤلفون: Takanashi S; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Kondo Y; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Saito S; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Kikuchi J; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Hanaoka H; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Kaneko Y; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
المصدر: International journal of rheumatic diseases [Int J Rheum Dis] 2023 Nov; Vol. 26 (11), pp. 2240-2247. Date of Electronic Publication: 2023 Sep 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-185X (Electronic) Linking ISSN: 17561841 NLM ISO Abbreviation: Int J Rheum Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Oxford, UK] : Wiley on behalf of the Asia Pacific League of Associations for Rheumatology
مواضيع طبية MeSH: Antirheumatic Agents*/adverse effects , Rheumatoid Vasculitis*/drug therapy , Arthritis, Rheumatoid*/diagnosis , Arthritis, Rheumatoid*/drug therapy , Lymphoproliferative Disorders*/drug therapy, Humans ; Rituximab/adverse effects ; Glucocorticoids/adverse effects ; Retrospective Studies ; Treatment Outcome ; Severity of Illness Index
مستخلص: Objectives: To elucidate the efficacy and safety of rituximab in special types of rheumatoid arthritis.
Methods: We retrospectively reviewed all patients with rheumatoid arthritis with lymphoproliferative disorder or vasculitis treated with rituximab between April 2010 and June 2022 at Keio University Hospital. We assessed the effectiveness of rituximab using the Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), and safety of rituximab during the disease course. We also assessed the glucocorticoid-sparing effects of rituximab.
Results: We included eight patients with a history of lymphoproliferative disorder and five patients with rheumatoid vasculitis. They were treated with rituximab without high-dose glucocorticoid. The mean DAS28-ESR and CDAI scores significantly improved 12 months after rituximab administration (DAS28-ESR, 4.7 vs. 2.7, p < .001; CDAI, 16.0 vs. 5.1, p = .006, respectively), and the dose of prednisolone was reduced from a mean of 7.4 mg/day to 4.0 mg/day at 12 months (p = .05) and 3.2 mg/day at the last visit (p = .04). During the mean follow-up period of 52 months, we recorded one recurrence of lymphoproliferative disorder (not B-cell type) in patients with a history of lymphoproliferative disorder and remarkable improvement of skin ulcers in patients with vasculitis.
Conclusion: B-cell depletion by rituximab may be a useful treatment option for patients with lymphoproliferative disorder and rheumatoid vasculitis.
(© 2023 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
References: Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038.
Takanashi S, Kaneko Y, Takeuchi T. CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. Ann Rheum Dis. 2020;79:671-674.
Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36(2):88-98.
Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776.
Takanashi S, Nakazato T, Aisa Y, et al. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. Ann Hematol. 2018;97(9):1611-1618.
Takanashi S, Aisa Y, Ito C, et al. C1linical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 2017;37(10):1629-1633.
Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791-1802.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588.
Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33(2):65-72.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458.
Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60(11):5247-5256.
Takanashi S, Kaneko Y, Takeuchi T. Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1491-1493.
Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019;59(2):72-92.
Nakazato T, Takanashi S, Hirano M, et al. Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma. Ann Hematol. 2018;97(8):1489-1491.
Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33-36.
Westedt ML, Herbrink P, Molenaar JL, et al. Rheumatoid factors in rheumatoid arthritis and vasculitis. Rheumatol Int. 1985;5(5):209-214.
Siegert CE, Daha MR, van der Voort EA, Breedveld FC. IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis. Arthritis Rheum. 1990;33(11):1646-1654.
فهرسة مساهمة: Keywords: B-cell depletion; extra-articular lesion; lymphoproliferative disorder; rheumatoid arthritis; rheumatoid vasculitis; rituximab
المشرفين على المادة: 4F4X42SYQ6 (Rituximab)
0 (Antirheumatic Agents)
0 (Glucocorticoids)
تواريخ الأحداث: Date Created: 20230914 Date Completed: 20231102 Latest Revision: 20231102
رمز التحديث: 20231215
DOI: 10.1111/1756-185X.14920
PMID: 37705311
قاعدة البيانات: MEDLINE
الوصف
تدمد:1756-185X
DOI:10.1111/1756-185X.14920